Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Declares 28-Cent Third-Quarter 2015 Dividend

Business Wire June 25, 2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

Business Wire June 24, 2015

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

Business Wire June 23, 2015

Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts

Business Wire June 23, 2015

New Online Community, Quitter's Circle, Helps Smokers Trade Cigarettes for Real-Time Support

Business Wire June 23, 2015

Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaban)

GlobeNewswire June 22, 2015

Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline

Business Wire June 22, 2015

Pfizer Consumer Healthcare To Expand Caltrate And Centrum Production In China

Business Wire June 15, 2015

Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder

Business Wire June 11, 2015

Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)

Business Wire June 10, 2015

Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology

Business Wire June 8, 2015

Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging through New Campaign

Business Wire June 4, 2015

Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

Business Wire May 30, 2015

Pfizer's RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

Business Wire May 29, 2015

Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

Business Wire May 28, 2015

Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health

Business Wire May 28, 2015

Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

Business Wire May 19, 2015

Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira

Business Wire May 14, 2015

Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors

Business Wire May 14, 2015

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

Business Wire May 13, 2015